Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis
复制标题
DOI：
10.5754/hge11729
复制
发表时间：
2012-07-01
影响因子：
--
通讯作者：
Sofuni, Atsushi
中科院分区：
文献类型：
--
作者：
Kasuya, Kazuhiko;Tsuchida, Akihiko;Sofuni, Atsushi
背景/目的：ATP结合盒转运蛋白基因的单核苷酸多态性（SNP）与抗癌药物的副作用相关，药物代谢相关酶基因的单核苷酸多态性（SNP）参与吉西他滨（GEM）的激活。方法：对 48 名胰腺癌切除后接受辅助 GEM 化疗的患者进行多药耐药 1 (MDR1) 2677、MDR1 3435、乳腺癌耐药蛋白 (BCRP) 421、核糖核苷酸还原酶 M1 (RRM1)(-)524、RRM1(-)37 和脱氧胞苷的 SNP 检测。 脱氨酶（CDA）208。我们将患者分为正常组：野生型等位基因纯合的患者或突变等位基因杂合的患者和突变组：突变等位基因纯合的患者。比较两组的结果以及副作用的发生和严重程度。结果：MDR1 2677、MDR1 3435、BCRP421、RRM1(-) 524、RRM1(-) 37 和 CDA 突变组分别占 37.5%、31.3%、0%、12.5%、4.2% 和 4.2%。 MDR1 2677 突变组中 >= G3 副作用的发生率最高，为 39%。 MDR1 2677 突变组的无病生存期和总生存期往往更长。结论：MDR1 2677 的 SNP 与接受 GEM 化疗的患者的药物反应之间存在相关性。
Background/Aims: Single nucleotide polymorphism (SNP) of the genes for ATP-binding cassette transporters is related to the side effects of anticancer drugs and that of drug metabolism-related enzyme genes is involved in the activation of gemcitabine (GEM). Methodology: Forty eight patients treated with adjuvant GEM chemotherapy after pancreatic cancer resection was examined for the SNP of multidrug-resistance 1 (MDR1) 2677, MDR1 3435, breast cancer resistance protein (BCRP) 421, ribonucleotide reductase M1 (RRM1)(-)524, RRM1(-)37 and deoxycytidine deaminase (CDA) 208. We divided the patients according to normal group: patients homozygous for a wild-type allele or heterozygous for a mutant allele and mutant group: those homozygous for a mutant allele. Both groups were compared regarding the outcome and the occurrence and severity of side effects. Results: MDR1 2677, MDR1 3435, BCRP421, RRM1(-) 524, RRM1(-) 37 and CDA mutant groups comprised 37.5, 31.3, 0, 12.5, 4.2 and 4.2%, respectively. The occurrence of >= G3 side effects was the most frequent in the MDR1 2677 mutant group at 39%. The disease-free survival and overall survival tended to be longer in the MDR1 2677 mutant group. Conclusions: A correlation between the SNP of MDR1 2677 and drug response in patients receiving GEM chemotherapy.